Novo Nordisk’s Ozempic
FDA finds no evidence that Ozempic, similar drugs cause suicidal thoughts in preliminary evaluation
The US Food and Drug Administration said Thursday that a preliminary evaluation of reports of suicidal thoughts or actions among people taking drugs like Ozempic and Wegovy for type 2 diabetes and weight loss has not found evidence that the drugs cause those effects.
The agency said in a statement that it conducted “detailed reviews” over the last several months of reports received in its FDA Adverse Event Reporting System, or FAERS. It noted that because “the information was often limited and because these events can be influenced by other factors, we determined that the information in these reports did not demonstrate a clear relationship with the use of GLP-1 (receptor agonists).”
GLP-1 receptor agonists are the class of drugs that includes Ozempic and Wegovy, as well as Mounjaro and Zepbound.